# reload+after+2024-01-20 20:43:53.940240
address1§10865 Road to the Cure
address2§Suite 150
city§San Diego
state§CA
zip§92121
country§United States
phone§858 727 1755
website§https://www.capricor.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
fullTimeEmployees§74
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Frank Isaac Litvack FACC, M.D.', 'age': 67, 'title': 'Executive Chairman of the Board', 'yearBorn': 1956, 'fiscalYear': 2022, 'totalPay': 120000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Linda  Marbán Ph.D.', 'age': 60, 'title': 'Co-Founder, President, CEO & Director', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 282300, 'exercisedValue': 0, 'unexercisedValue': 1021739}, {'maxAge': 1, 'name': 'Mr. Anthony J. Bergmann M.B.A.', 'age': 37, 'title': 'CFO & Corporate Treasurer', 'yearBorn': 1986, 'fiscalYear': 2022, 'totalPay': 459150, 'exercisedValue': 0, 'unexercisedValue': 312174}, {'maxAge': 1, 'name': 'Ms. Karen G. Krasney', 'age': 70, 'title': 'Executive VP, General Counsel & Secretary', 'yearBorn': 1953, 'fiscalYear': 2022, 'totalPay': 434532, 'exercisedValue': 0, 'unexercisedValue': 267464}, {'maxAge': 1, 'name': 'Dr. Eduardo  Marbán', 'title': 'Co-Founder & Chairman of Scientific Advisory Board', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Kristi A. H. Elliott Ph.D.', 'title': 'Chief Science Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Catherine Lee Kelleher', 'title': 'Consultant', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§3.935
priceToSalesTrailing12Months§11.900845
currency§USD
dateShortInterest§1702598400
forwardEps§-0.91
exchange§NCM
quoteType§EQUITY
shortName§Capricor Therapeutics, Inc.
longName§Capricor Therapeutics, Inc.
firstTradeDateEpochUtc§1171377000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§b35219ff-6920-3123-948e-679f94571f52
gmtOffSetMilliseconds§-18000000
targetHighPrice§40.0
targetLowPrice§12.0
targetMeanPrice§22.33
targetMedianPrice§15.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§3
quickRatio§0.883
grossMargins§-0.55282
ebitdaMargins§-2.12885
trailingPegRatio§None
